Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.

Minozzi, Silvia; Lytras, Theodore; Gianola, Silvia; Gonzalez-Lorenzo, Marien; Castellini, Greta; Galli, Cristina; Cereda, Danilo; Bonovas, Stefanos; Pariani, Elena; Moja, Lorenzo

Minozzi, Silvia; Lytras, Theodore; Gianola, Silvia; Gonzalez-Lorenzo, Marien; Castellini, Greta; Galli, Cristina; Cereda, Danilo; Bonovas, Stefanos; Pariani, Elena; Moja, Lorenzo.

Afiliación

Minozzi S; Department of Epidemiology, Lazio regional health Service, Rome, Italy.
Lytras T; School of Medicine, European University Cyprus, Nicosia, Cyprus.
Gianola S; IRCCS Istituto Ortopedico Galeazzi, Unit of Clinical Epidemiology, Milan, Italy.
Gonzalez-Lorenzo M; Laboratory of Clinical Research Methodology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Castellini G; IRCCS Istituto Ortopedico Galeazzi, Unit of Clinical Epidemiology, Milan, Italy.
Galli C; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Cereda D; Directorate General for Health, Lombardy Region, Milan, Italy.
Bonovas S; Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy.
Pariani E; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
Moja L; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

EClinicalMedicine ; 46: 101331, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35360146

Palabras clave

3-IIV HD, trivalent inactivated high-dose influenza vaccine; 3-IIV ID, trivalent inactivated intradermal influenza vaccine; 3-IIV MF59/AS03-adj, trivalent inactivated influenza vaccine adjuvanted with MF59/AS03; 3-IIV vir/lip-adj, trivalent inactivated influenza vaccine adjuvanted with virosome/liposome; 3-IIV, trivalent inactivated influenza vaccine; 3-LAIV, trivalent live-attenuated influenza vaccine; 3-RIV, trivalent recombinant influenza vaccine; 4-IIV HD, quadrivalent inactivated high-dose influenza vaccine; 4-IIV ID, quadrivalent inactivated intradermal influenza vaccine; 4-IIV MF59/AS03-adj, quadrivalent inactivated influenza vaccine adjuvanted with MF59/AS03; 4-IIV vir/lip-adj, quadrivalent inactivated influenza vaccine adjuvanted with virosome/liposome; 4-IIV, quadrivalent inactivated influenza vaccine; 4-LAIV, quadrivalent live-attenuated influenza vaccine; 4-RIV, quadrivalent recombinant influenza vaccine; AE, adverse event; CI, confidence interval; CrI, credible interval; IIV, inactivated influenza vaccine; ILI, influenza-like illness; Influenza; LAIV, live-attenuated influenza vaccine; NMA, network meta-analysis; Network meta-analysis; RCT, randomized controlled trial; RIV, recombinant influenza vaccine; RR, risk ratio; SUCRA, surface under the cumulative ranking curve; Systematic review; Vaccines

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 7_ODS3_muertes_prevenibles_nacidos_ninos Problema de salud: 2_muertes_prevenibles / 7_infections Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Revista: EClinicalMedicine Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google